CDH1 and skin cancer: Dose-dependent increase of E-cadherin in ERB-041 treatment in skin cancer has been documented with 20 μM as the lowest dose [17], our data showed 10 μM ERB-041 could not altere E-cadherin expression in ovarian cancer cells, suggesting higher dose may be needed which could be further studied in future study.